Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis

Sarah Dhaiban, Mena Al-Ani, Noha Mousaad Elemam, Azzam A Maghazachi College of Medicine and Immuno-Oncology Group, Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab EmiratesCorrespondence: Azzam A MaghazachiDepartment of Clinical Sciences, College of Medicine, Unive...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dhaiban S, Al-Ani M, Elemam NM, Maghazachi AA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	multiple sclerosis experimental autoimmune encephalomyelitis chemokines chemokines receptors. Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/9bfd1473d8b24391aa84c3248f0b7ec4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9bfd1473d8b24391aa84c3248f0b7ec4
record_format	dspace
spelling	oai:doaj.org-article:9bfd1473d8b24391aa84c3248f0b7ec42021-12-02T08:34:55ZTargeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis1178-7031https://doaj.org/article/9bfd1473d8b24391aa84c3248f0b7ec42020-09-01T00:00:00Zhttps://www.dovepress.com/targeting-chemokines-and-chemokine-receptors-in-multiple-sclerosis-and-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Sarah Dhaiban, Mena Al-Ani, Noha Mousaad Elemam, Azzam A Maghazachi College of Medicine and Immuno-Oncology Group, Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab EmiratesCorrespondence: Azzam A MaghazachiDepartment of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, United Arab EmiratesEmail amagazachi@sharjah.ac.aeAbstract: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative disorder that results in inflammation and demyelination of the central nervous system (CNS). MS symptoms include walking difficulties, visual weakening, as well as learning and memory impairment, thus affecting the quality of the patient’s life. Chemokines and chemokine receptors are expressed on the immune cells as well as the CNS resident cells. Several sets of chemokine receptors and their ligands tend to be pathogenic players in MS, including CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL17, CCL19, CCL21, CCL22, CXCL1, CXCL8, CXCL9, CXCL10, CXCL11, and CXCL16. Furthermore, current modulatory drugs that are used in the treatment of MS and its animal model, the experimental autoimmune encephalomyelitis (EAE), affect the expression of several chemokine and chemokine receptors. In this review, we highlight the pathogenic roles of chemokines and their receptors as well as utilizing them as potential therapeutic targets through selective agents, such as specific antibodies and receptor blockers, or indirectly through MS or EAE immunomodulatory drugs.Keywords: multiple sclerosis, experimental autoimmune encephalomyelitis, chemokines, chemokine receptorsDhaiban SAl-Ani MElemam NMMaghazachi AADove Medical Pressarticlemultiple sclerosisexperimental autoimmune encephalomyelitischemokineschemokines receptors.PathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 13, Pp 619-633 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	multiple sclerosis experimental autoimmune encephalomyelitis chemokines chemokines receptors. Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	multiple sclerosis experimental autoimmune encephalomyelitis chemokines chemokines receptors. Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Dhaiban S Al-Ani M Elemam NM Maghazachi AA Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
description	Sarah Dhaiban, Mena Al-Ani, Noha Mousaad Elemam, Azzam A Maghazachi College of Medicine and Immuno-Oncology Group, Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab EmiratesCorrespondence: Azzam A MaghazachiDepartment of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, United Arab EmiratesEmail amagazachi@sharjah.ac.aeAbstract: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative disorder that results in inflammation and demyelination of the central nervous system (CNS). MS symptoms include walking difficulties, visual weakening, as well as learning and memory impairment, thus affecting the quality of the patient’s life. Chemokines and chemokine receptors are expressed on the immune cells as well as the CNS resident cells. Several sets of chemokine receptors and their ligands tend to be pathogenic players in MS, including CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL17, CCL19, CCL21, CCL22, CXCL1, CXCL8, CXCL9, CXCL10, CXCL11, and CXCL16. Furthermore, current modulatory drugs that are used in the treatment of MS and its animal model, the experimental autoimmune encephalomyelitis (EAE), affect the expression of several chemokine and chemokine receptors. In this review, we highlight the pathogenic roles of chemokines and their receptors as well as utilizing them as potential therapeutic targets through selective agents, such as specific antibodies and receptor blockers, or indirectly through MS or EAE immunomodulatory drugs.Keywords: multiple sclerosis, experimental autoimmune encephalomyelitis, chemokines, chemokine receptors
format	article
author	Dhaiban S Al-Ani M Elemam NM Maghazachi AA
author_facet	Dhaiban S Al-Ani M Elemam NM Maghazachi AA
author_sort	Dhaiban S
title	Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
title_short	Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
title_full	Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
title_fullStr	Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
title_full_unstemmed	Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
title_sort	targeting chemokines and chemokine receptors in multiple sclerosis and experimental autoimmune encephalomyelitis
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/9bfd1473d8b24391aa84c3248f0b7ec4
work_keys_str_mv	AT dhaibans targetingchemokinesandchemokinereceptorsinmultiplesclerosisandexperimentalautoimmuneencephalomyelitis AT alanim targetingchemokinesandchemokinereceptorsinmultiplesclerosisandexperimentalautoimmuneencephalomyelitis AT elemamnm targetingchemokinesandchemokinereceptorsinmultiplesclerosisandexperimentalautoimmuneencephalomyelitis AT maghazachiaa targetingchemokinesandchemokinereceptorsinmultiplesclerosisandexperimentalautoimmuneencephalomyelitis
_version_	1718398456110776320

Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis

Ejemplares similares